Insider Selling: Blueprint Medicines Co. (NASDAQ:BPMC) COO Sells $216,075.48 in Stock

Blueprint Medicines Co. (NASDAQ:BPMC) COO Christina Rossi sold 2,274 shares of the business’s stock in a transaction that occurred on Monday, March 24th. The stock was sold at an average price of $95.02, for a total transaction of $216,075.48. Following the completion of the sale, the chief operating officer now owns 69,266 shares in the company, valued at $6,581,655.32. The trade was a 3.18 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Christina Rossi also recently made the following trade(s):

• On Tuesday, January 21st, Christina Rossi sold 2,274 shares of Blueprint Medicines stock. The stock was sold at an average price of $110.14, for a total transaction of $250,458.36.

Blueprint Medicines Trading Down 1.1 %

NASDAQ:BPMC opened at $88.72 on Friday. The company has a debt-to-equity ratio of 1.15, a quick ratio of 2.80 and a current ratio of 2.85. The company has a market capitalization of $5.67 billion, a P/E ratio of -82.15 and a beta of 0.58. The stock’s 50 day moving average price is $98.13 and its 200 day moving average price is $93.93. Blueprint Medicines Co. has a 52 week low of $80.68 and a 52 week high of $121.90.

Blueprint Medicines (NASDAQ:BPMC) last announced its quarterly earnings results on Thursday, February 20th. The biotechnology company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.11). Blueprint Medicines had a negative return on equity of 77.49% and a negative net margin of 13.19%. On average, research analysts forecast that Blueprint Medicines Co. will post -1.28 EPS for the current fiscal year.

Institutional Trading of Blueprint Medicines

A number of institutional investors and hedge funds have recently made changes to their positions in BPMC. Quarry LP acquired a new position in shares of Blueprint Medicines during the 3rd quarter valued at about $32,000. R Squared Ltd acquired a new position in Blueprint Medicines during the fourth quarter valued at approximately $51,000. Headlands Technologies LLC bought a new position in shares of Blueprint Medicines in the fourth quarter valued at approximately $65,000. Thematics Asset Management acquired a new stake in shares of Blueprint Medicines in the fourth quarter worth $72,000. Finally, Covestor Ltd boosted its holdings in shares of Blueprint Medicines by 62.7% during the 4th quarter. Covestor Ltd now owns 973 shares of the biotechnology company’s stock worth $85,000 after buying an additional 375 shares during the period.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. StockNews.com lowered Blueprint Medicines from a “hold” rating to a “sell” rating in a research note on Monday, March 3rd. Piper Sandler increased their price target on Blueprint Medicines from $109.00 to $119.00 and gave the company a “neutral” rating in a research report on Monday, January 27th. Scotiabank started coverage on Blueprint Medicines in a report on Friday, March 7th. They set a “sector outperform” rating and a $150.00 price objective on the stock. HC Wainwright reiterated a “buy” rating and issued a $135.00 target price on shares of Blueprint Medicines in a report on Friday, February 14th. Finally, Stephens restated an “overweight” rating and set a $140.00 price target on shares of Blueprint Medicines in a report on Thursday, January 2nd. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Blueprint Medicines has a consensus rating of “Moderate Buy” and a consensus target price of $124.95.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.